Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom

a thin film, non-self-aggregating technology, applied in the direction of respiratory disorder, digestive system, pharmaceutical non-active ingredients, etc., can solve the problem that the dosage form of pharmaceutical film has not been marketed largely to da

Inactive Publication Date: 2005-08-25
MONOSOL RX
View PDF99 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015] In a further aspect of the present invention, there is provided a film product that is formed by combining a polymer and a polar solvent, forming the combination into a film, and drying the film in a controlled manner, desirably by initially only applying heat to the bottom side of the film, in order to maintain a non-self-aggregating uniform heterogeneity. Desirably, during the initial bottom drying stage, substantially no convection currents, i.e. hot air currents, are permitted to travel across the tops of the films. Once the visco-elastic properties of the film are such that the film components are “locked” in place and cannot move to cause non-uniformity, other methods of heating may then be employed. The polar solvent may be water, a polar organic solvent, or a combination thereof. An active ingredient may be added to the polymer and water combination prior to the drying step. Alternatively, or in addition to controlling the drying the film, the polymer may be selected in order to provide a viscosity that maintains the non-self-aggregating uniform heterogeneity. Moreover, the composition desirably is mixed in a manner to minimize the incorporation of air into the mixture and is desirably deaerated, such as by conditioning at room temperature, vacuum treatment or the like, to allow trapped air to escape prior to the drying process. This serves to eliminate bubble and void formation in the final film product, thereby further improving uniformity. Reverse roll is one particularly useful coating technique may also be used to form the film.

Problems solved by technology

Pharmaceutical film dosage forms to date have not been marketed largely due to the inability to achieve this result.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
  • Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
  • Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom

Examples

Experimental program
Comparison scheme
Effect test

examples

[0154] Water soluble thin film compositions of the present invention are prepared using the amounts described in Table 1.

TABLE 1Weight (g)IngredientABCDEFGHIHydroxypropylmethyl1.761.6332.003.6732.00cellulosePeppermint oil0.901.01.058.02.67Sweetener0.150.150.220.104.61.530.15Polyvinylpyrrolidone0.941.057.02.33Tween 8010.50.52.00.6511.801.350.511.80Simethicone20.20.20.150.301.800.210.21.80Listerine383.3583.35Methylcellulose6.0Cornstarch41.75Agar1.25Water42.2493.6339.22768.00280.088.24768.0Loratadine519.219.2Pullulan66.0Ibuprofen38.4

1Available from ICI Americas

2Available from OSI

3Available from Pfizer, Inc. including thymol (0.064%), eucalyptol (0.092%), methyl salicylate (0.060%), menthol (0.042%), water (up to 72.8%), alcohol (26.9%), benzoic acid, poloxamer 407, sodium benzoate, and caramel color

4Available from Grain Processing Corporation as Pure Cote B792

5Available from Schering Corporation as Claritin

6Available from Hayashibara Biochemical Laboratories, Inc., Japan

[0155] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weight percentaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 10 / 074,272, filed Feb. 14, 2002, the contents of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] The invention relates to rapidly dissolving films and methods of their preparation. The films may also contain an active ingredient that is evenly distributed throughout the film. The even or uniform distribution is achieved by controlling one or more parameters, and particularly the drying process that reduces aggregation or conglomeration of the components in the film as it forms into a solid structure.BACKGROUND OF THE RELATED TECHNOLOGY [0003] Active ingredients such as drugs or pharmaceuticals, may be prepared in a tablet form to allow for accurate and consistent dosing. However, this form of preparing and dispensing medications has many disadvantages including that a large proportion of adjuvants that must be added to obtain a size able to be handl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/00A61K9/16A61K9/70A61K45/00A61K47/32A61K47/34A61K47/36A61K47/38A61K47/42A61P1/04A61P11/10A61P11/14A61P25/04A61P25/16A61P29/00A61P31/04A61P37/08
CPCA61K9/006A61K9/1635A61K9/1652C08J5/18A61K9/7015A61K31/4545A61K9/7007A61K31/192A61K31/422A61K31/435A61K31/4525A61K31/80A61P1/00A61P1/04A61P11/10A61P11/14A61P25/04A61P25/16A61P29/00A61P31/04A61P37/08A61K9/0056A61K47/02A61K47/10A61K47/22A61K47/32A61K47/38A61K47/44A61K47/46
Inventor YANG, ROBERT K.FUISZ, RICHARD C.MYERS, GARY L.FUISZ, JOSEPH M.
Owner MONOSOL RX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products